Gene Therapy Follow up Protocol for Subjects Previously Enrolled in CAR T-Cell Studies
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- To provide long term follow up of patients previously enrolled on treatment protocols in the NCI ETIB Branch.
研究概览
简要总结
Background:
- Gene therapy is a way to treat or prevent disease using genes. It is monitored very closely by regulators because there can be long-term, unexpected side effects. NIH is required to try to contact people who have been treated with gene therapy at least annually for up to 15 years. This is to see if they have had any bad side effects. This trial does not include any therapy and is only for patients previously treated on gene-therapy trials at the NCI Surgery Branch who are no longer enrolled on their original gene therapy clinical trial.
Objective:
- To collect of long-term follow-up data on people who have been in gene transfer studies. This follow-up is required by regulators.
Eligibility:
- People age 18 and older who have been in a previous NCI Surgery Branch gene therapy research study.
Design:
- After they get the genetically modified cells, participants will:
- Have blood drawn 3, 6, and 12 months later.
- Have an annual clinic visit for the next 4 years. They will have a physical exam. They will answer questions about any signs of neurological, autoimmune, or blood disorders, or any new cancers. Blood may be drawn.
- Be called or emailed annually for the next 10 years. They will answer health questions. Blood samples may need to be taken.
- Participants will be asked for their current address and phone number. They will also be asked for the address and phone number of 1 or 2 people who will know their whereabouts. One of these should be a family member if possible,
- At the time of the participant s death, researchers will request permission from their family for an autopsy.
详细描述
Background:
-The National Cancer Institute Surgery Branch (NCI-SB) Branch investigator conducts clinical trials utilizing gene transfer. The current U.S. Food and Drug Administration (FDA) requirements for long term follow up may be up to fifteen years for some products. As this time period is frequently longer than studies are expected to be open, a long-term follow-up protocol is necessary to ensure the follow up of these subjects
Objectives:
-To facilitate collection of long term, follow up information on subjects who have participated in gene transfer studies as required by the U.S. Food and Drug Administration and other regulatory groups
Eligibility:
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who have received treatment on a CAR T-cell gene therapy protocol. Age >= 18 years as children are generally excluded from CAR T-cell gene therapy studies.
排除标准
- 未提供
研究组 & 干预措施
1/Cohort 1
Subjects who have received treatment on an NCI Surgery Branch CAR T-cell gene therapy protocols.
结局指标
主要结局
To provide long term follow up of patients previously enrolled on treatment protocols in the NCI ETIB Branch.
时间窗: 15 years
List of long time adverse event frequency after Gene therapy drug
次要结局
未报告次要终点